Lataa...
Therapeutic potential of JAK2 inhibitors
The discovery of an activating tyrosine kinase mutation JAK2V617F in myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF) has resulted in the development of JAK2 inhibitors, of which several are being evaluated in phase I/II clin...
Tallennettuna:
| Julkaisussa: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5166576/ https://ncbi.nlm.nih.gov/pubmed/20008249 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/asheducation-2009.1.636 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|